


18-02211-E

January 30 2018

US Securities & Exchange Commission
Office of FOIA and Privacy Act Operations
100 F Street, NE Mail Stop 5100
Washington, DC 20549-5100



Dear FOIA Office:

Under the Freedom of Information Act (FOIA), please send a copy of the following:

A copy of: Exhibit: 10.34 to the form 10-K/A filed by PROGENICS PHARMACEUTICALS INC on October 18, 2010

In the event confidential treatment has not expired provide the specific date for which confidential treatment is still in effect. I do not need a copy of the order. We authorize up to \$61.00 in processing fees. Thank You,

Paul D'Souza
Editor - Deals

Clarivate Analytics Friars House, 160 Blackfriars Road London, UK SE1 8EZ
Phone: +44-2074334789
paul.dsouza@clarivate.com



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
STATION PLACE
100 F STREET, NE
WASHINGTON, DC 20549-2465

Office of FOIA Services

February 2, 2018

Mr. Paul D'Souza
Clarivate Analytics
160 Blackfriars Road
London UK SE1 8EZ

RE: Freedom of Information Act (FOIA), 5 U.S.C. § 552
Request No. 18-02211-E

Dear Mr. D'Souza:

This letter is in response to your request, dated and received in this office on January 30, 2018, for Exhibit 10.34 (also filed as Exhibit 10.4 to the Form 10-Q filed August 9, 2005) to the Form 10-K/A filed by Progenics Pharmaceuticals, Inc. on October 18, 2010.

The Commission extended confidential treatment to Exhibit 10.4 to the Form 10-Q under Rule 24b-2 of the Securities and Exchange Act of 1934 through June 14, 2025. Since confidential treatment has been extended, we are providing the expiration date from the relevant CT order as requested.

If you have any questions, please contact me at morrowa@sec.gov or (202) 551-8376. You may also contact me at foiapa@sec.gov or (202) 551-7900. You also have the right to seek assistance from a FOIA Public Liaison, Jeffery Ovall at (202) 551-7900.

Sincerely,

A handwritten signature in black ink that reads "Alysia Morrow".

Alysia Morrow
FOIA Research Specialist